Novo Nordisk (NVO) has received the recommendation of the European Medicines Agency's Committee for Medicinal Products for Human Use for the extension of the current indication for Saxenda, according to a Friday statement from the regulator.

The update in Saxenda's marketing authorization, once approved, will include the treatment of children aged 6 years to less than 12 years, the EMA said.

Saxenda is currently indicated as an "adjunct to healthy nutrition and increased physical activity for weight management," according to the statement.

Price: 67.52, Change: -0.65, Percent Change: -0.95